• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过定量免疫化学粪便潜血筛查试验识别结直肠腺瘤取决于腺瘤特征、所采用的发展阈值以及所进行的检测次数。

Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.

作者信息

Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Leshno M, Niv Y

机构信息

Gastroenterology Department, Rabin Medical Center, Beilinson Hospital, Petach Tikva.

出版信息

Aliment Pharmacol Ther. 2009 Apr 15;29(8):906-17. doi: 10.1111/j.1365-2036.2009.03946.x.

DOI:10.1111/j.1365-2036.2009.03946.x
PMID:19183147
Abstract

BACKGROUND

Faecal occult blood tests (FOBT) are faulted by low sensitivity for advanced adenomatous polyps (AAP). Quantified, immunochemical, haemoglobin (Hb)-specific immunochemical FOBT (I-FOBT) measurements are now used for colorectal screening.

AIMS

To correlate adenoma characteristics to amount of faecal Hb lost and to evaluate sensitivity and specificity for AAP by faecal Hb development threshold used and number of I-FOBTs collected.

METHODS

Three daily I-FOBTs were collected and analysed in 1221 patients scheduled for colonoscopy. Faecal Hb was analysed as ngHb/mL of buffer and the highest result related to colonoscopy findings.

RESULTS

In 1204 patients without cancer, colonoscopy identified adenomas in 294, 99 with AAPs. Adenoma patients had elevated faecal Hb increasing with advanced histology, size, pedunculated shape and multiplicity (P < 0.001 for all). At 50 ngHb/mL threshold, sensitivity and specificity for AAPs were 54.5% (95%CI 44.7, 64.7) and 88.1% (95%CI 86.2, 90.1) for three tests. At higher thresholds, sensitivity decreased, but was significantly higher with more samples collected. Conversely, specificity increased at higher thresholds, but decreased with more samples.

CONCLUSIONS

Faecal Hb loss from adenomas is significantly associated with size, number and advanced features. Sensitivity and specificity for AAPs are determined by test threshold chosen and number of samples collected; these determine the number of colonoscopies needed for positive tests.

摘要

背景

粪便潜血试验(FOBT)对进展期腺瘤性息肉(AAP)的敏感性较低。目前,定量、免疫化学、血红蛋白(Hb)特异性免疫化学粪便潜血试验(I-FOBT)测量用于结直肠癌筛查。

目的

将腺瘤特征与粪便Hb丢失量相关联,并通过所使用的粪便Hb发展阈值和收集的I-FOBT数量评估AAP的敏感性和特异性。

方法

对1221例计划进行结肠镜检查的患者收集并分析连续三天的I-FOBT。粪便Hb分析为每毫升缓冲液中的纳克Hb(ngHb/mL),最高结果与结肠镜检查结果相关。

结果

在1204例无癌症患者中,结肠镜检查发现294例有腺瘤,其中99例有AAP。腺瘤患者的粪便Hb升高,随着组织学进展、大小、有蒂形状和多发性增加(所有P<0.001)。在50 ngHb/mL阈值下,三次检测对AAP的敏感性和特异性分别为54.5%(95%CI 44.7, 64.7)和88.1%(95%CI 86.2, 90.1)。在更高的阈值下,敏感性降低,但收集更多样本时显著更高。相反,特异性在更高阈值时增加,但随着样本增多而降低。

结论

腺瘤导致的粪便Hb丢失与大小、数量和进展特征显著相关。AAP的敏感性和特异性由所选的检测阈值和收集的样本数量决定;这些决定了阳性检测所需的结肠镜检查数量。

相似文献

1
Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.通过定量免疫化学粪便潜血筛查试验识别结直肠腺瘤取决于腺瘤特征、所采用的发展阈值以及所进行的检测次数。
Aliment Pharmacol Ther. 2009 Apr 15;29(8):906-17. doi: 10.1111/j.1365-2036.2009.03946.x.
2
Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.免疫化学粪便潜血试验和灵敏愈创木脂试验检测重大结直肠肿瘤相对效率的结肠镜定量评估
Aliment Pharmacol Ther. 2009 Feb 15;29(4):450-7. doi: 10.1111/j.1365-2036.2008.03898.x. Epub 2008 Nov 17.
3
Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.一种自动开发的定量免疫化学粪便潜血筛查试验的性能特征与评估
Am J Gastroenterol. 2005 Nov;100(11):2519-25. doi: 10.1111/j.1572-0241.2005.00231.x.
4
Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy?高危结直肠肿瘤且粪便定量免疫化学检测阴性的患者能否推迟择期结肠镜检查?
Aliment Pharmacol Ther. 2010 Feb 15;31(4):523-33. doi: 10.1111/j.1365-2036.2009.04202.x. Epub 2009 Nov 19.
5
Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use.定量免疫化学粪便隐血试验的累积评估,以确定其最佳临床应用。
Cancer. 2010 May 1;116(9):2115-25. doi: 10.1002/cncr.25012.
6
Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.在筛查人群中对粪便潜血愈创木脂法检测和免疫化学法检测用于结直肠癌筛查的随机对照比较。
Gastroenterology. 2008 Jul;135(1):82-90. doi: 10.1053/j.gastro.2008.03.040. Epub 2008 Mar 25.
7
Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population.CT结肠成像、结肠镜检查、乙状结肠镜检查和粪便潜血试验用于检测平均风险人群中进展性腺瘤的比较。
Gut. 2009 Feb;58(2):241-8. doi: 10.1136/gut.2008.156448. Epub 2008 Oct 13.
8
Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?对非综合征性家族性结直肠癌风险患者进行粪便潜血定量检测能否预先确定其是否需要进行结肠镜检查?
Aliment Pharmacol Ther. 2006 Nov 15;24(10):1475-81. doi: 10.1111/j.1365-2036.2006.03152.x. Epub 2006 Oct 10.
9
Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.使用新型粪便潜血试验筛查结直肠肿瘤:性能特征的最新进展。
J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70. doi: 10.1093/jnci/djm150. Epub 2007 Sep 25.
10
Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants.对于肿瘤形成,定量免疫化学粪便潜血试验的敏感性(而非特异性)会因使用低剂量阿司匹林、非甾体抗炎药和抗凝剂而略有增加。
Am J Gastroenterol. 2009 Apr;104(4):933-8. doi: 10.1038/ajg.2009.14. Epub 2009 Mar 17.

引用本文的文献

1
Utility of Stool-Based Tests for Colorectal Cancer Detection: A Comprehensive Review.基于粪便检测在结直肠癌检测中的应用:一项综述
Healthcare (Basel). 2024 Aug 18;12(16):1645. doi: 10.3390/healthcare12161645.
2
Adenoma location, size, and morphology are risk factors for FOBT false-negative results in inpatients with advanced colorectal adenoma.腺瘤位置、大小和形态是住院的伴有晚期结直肠腺瘤患者粪便隐血试验假阴性结果的危险因素。
Sci Rep. 2024 Jan 8;14(1):831. doi: 10.1038/s41598-024-51377-0.
3
A Multi-Centre Study to Risk Stratify Colorectal Polyp Surveillance Patients Utilising Volatile Organic Compounds and Faecal Immunochemical Test.
一项利用挥发性有机化合物和粪便免疫化学检测对结直肠癌息肉监测患者进行风险分层的多中心研究。
Cancers (Basel). 2022 Oct 9;14(19):4951. doi: 10.3390/cancers14194951.
4
The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma.粪便微生物群和氨基酸检测和监测腺瘤患者的潜力。
Gut Microbes. 2022 Jan-Dec;14(1):2038863. doi: 10.1080/19490976.2022.2038863.
5
Analysis of volatile organic compounds released from SW480 colorectal cancer cells and the blood of tumor-bearing mice.对SW480结肠癌细胞和荷瘤小鼠血液中释放的挥发性有机化合物的分析。
Transl Cancer Res. 2019 Dec;8(8):2736-2751. doi: 10.21037/tcr.2019.10.21.
6
Comparative effectiveness of five fecal immunochemical tests using colonoscopy as the gold standard: study protocol.五种粪便免疫化学检测方法与结肠镜检查对照的有效性研究:研究方案。
Contemp Clin Trials. 2021 Jul;106:106430. doi: 10.1016/j.cct.2021.106430. Epub 2021 May 8.
7
Future Prospects of Colorectal Cancer Screening: Characterizing Interval Cancers.结直肠癌筛查的未来前景:间隔期癌症的特征分析
Cancers (Basel). 2021 Mar 16;13(6):1328. doi: 10.3390/cancers13061328.
8
Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study.定量粪便免疫化学检测用于检测结直肠高级别瘤变的性能:一项前瞻性队列研究。
BMC Cancer. 2018 May 2;18(1):509. doi: 10.1186/s12885-018-4402-x.
9
Which Fecal Immunochemical Test Should I Choose?我应该选择哪种粪便免疫化学检测?
J Prim Care Community Health. 2017 Oct;8(4):264-277. doi: 10.1177/2150131917705206. Epub 2017 Apr 27.
10
Developments in Screening Tests and Strategies for Colorectal Cancer.结直肠癌筛查试验与策略的进展
Biomed Res Int. 2015;2015:326728. doi: 10.1155/2015/326728. Epub 2015 Oct 4.